ABSTRACT
Prunellae Spica is the dry ear of the labiaceae plant Prunella vulgaris， which is a traditional medicine and food plant with many functions. Prunellae Spica can clear liver-fire， improve eyesight， disperse knot detumescence. It owns hot and bitter flavors and cold property. It goes to the liver， gallbladder meridian， and is a kind of commonly-used antifebric. Prunellae Spica has been used in the treatment of mammary gland diseases since ancient times.The mammary abscess， mammary nodules， mammary carcinoma of traditional Chinese medicine all belong to breast disease， and the liver meridian is most closely related to these diseases. With the development of social life， breast disease has gradually become the most primary health problem for women. Modern pharmacological studies show that Prunellae Spica contains terpenoids， phenolic acids， flavonoids and other biological active components， which have anti-inflammatory， antibacterial， hormone regulation， anti-tumor and other effects. Prunellae Spica inhibits the p38 mitogen-activated protein kinase （p38 MAPK）/nuclear factor kappa-B （NF-κB） pathway to play an anti-mastitis role， interferes with the effects of estrogen receptors or regulates lipid levels to treat breast hyperplasia， and treats breast cancer through promoting the apoptosis of breast cancer cells， inhibiting the migration of breast cancer cells， regulating the division of breast cancer cells and other ways. While referring to the relevant literature， it was found that Prunellae Spica often exerted pharmacological effects through multi-channels and multi-target regulation， but most of the studies did not specify the specific target of its effect， which needs further study. In this review， the effects and mechanisms of Prunellae Spica in the treatment of various breast diseases were summarized， so as to provide a reference for further research on the wider clinical therapeutic effects of Prunella subtilis and its therapeutic effects on breast diseases.
ABSTRACT
Objective: To investigate the variation of genes associated with Usher syndrome type 1(USH1)in 136 Chinese deafness families from Henan province. Methods: The data of 136 deafness families tested by next-generation sequencing(NGS) which identified in the center of genetics and prenatal diagnosis of the First Affiliated Hospital of Zhengzhou University from November 2016 to December 2019 were analysized and the variation frequency of six genes related to Usher syndrome type 1(MYO7A, USH1C, CDH23, PCDH15, USH1G, CIB2) were summarized. Results: Five deafness families were detected nine pathogenic or likely pathogenic variations in two genes, accounting for 3.7% of all families. Among them, four families were caused by MYO7A variations and one family was caused by CDH23 variation. Meanwhile, seven variations of two genes were reported for the first time. They were c.313delG, c.5257dupA, c.5435A>T, c.5636G>C, c.5722T>G of MYO7A, and c.155_166del, c.4802delA of CDH23. The patients' vision of family 2 and family 3 had no obvious abnormality at present, but according to genetic diagnosis and walking dealy, they were considered to be USH1. Conclusions: MYO7A is the most common caustive gene associated with USH1 in Henan deafness patients, the application of next-generation sequencing technology can make USH1 patients diagnosed earlier before the visual symptoms appear.
Subject(s)
Humans , China/epidemiology , DNA Mutational Analysis , Deafness/genetics , Mutation , Myosin VIIa , Myosins/genetics , Pedigree , Usher Syndromes/geneticsABSTRACT
<p><b>BACKGROUND AND OBJECTIVE</b>Cytokine-induced killer (CIK) cells and autologous dendritic cells-CIK (DC-CIK) cells co-cultured with autologous dendritic cells (DCs) and CIK cells are commonly used for immunotherapy recently. We compared the anti-tumor immune response of CIK cells, autologous DC-CIK cells, and semi-allogeneic DC-CIK cells to explore a more effective anti-tumor adoptive immunotherapy approach.</p><p><b>METHODS</b>Peripheral monocytes were isolated from patients with renal carcinoma, lung cancer, or maxillary squamous cell carcinoma and their healthy adult children. Isolated cells were cultured and induced as DCs and CIK cells in vitro. CIK cells from patients were co-cultured with autologous DCs and DCs from their children respectively, generating DC-CIK cells and semi-allogeneic DC-CIK cells. The anti-tumor activities of autologous CIK cells, autologous DC-CIK cells, and semi-allogeneic DC-CIK cells were measured by LDH assay. Intracellular staining was used to test the secretion of cytokines. Flow cytometry was applied for detecting the phonotype changes of these three types of cells. Cell proliferation and cell apoptosis were detected by 5,6-carboxyfluorescein diacetate succinimidyl ester (CFSE) and Annexin V/PI respectively.</p><p><b>RESULTS</b>Compared with autologous CIK cells and DC-CIK cells, semi-allogeneic DC-CIK cells significantly enhanced the anti-tumor activity and IFN-gamma secretion, reduced IL-4 secretion, increased the ratio of CD3(+)CD56(+) cells and CD3(+)CD8(+) cells, decreased the number of CD4(+)CD25(+) cells, promoted cell proliferation, and lessened cell apoptosis.</p><p><b>CONCLUSIONS</b>Semi-allogeneic DC-CIK cells had a stronger anti-tumor effect than did autologous CIK cells and DC-CIK cells. Our results provided experimental evidence for clinical application of DC-CIK cells.</p>